Akums Drugs and Pharmaceuticals has reported its financial performance for the quarter and year ended March 31, 2026. The Board of Directors has recommended a total dividend of ₹3.00 per share, consisting of a final dividend of ₹1.00 and a special dividend of ₹2.00 per equity share. The company also announced key leadership changes in human resources and confirmed the upcoming 22nd Annual General Meeting scheduled for July 10, 2026.
Financial Performance Highlights
For the fiscal year ended March 31, 2026, Akums Drugs and Pharmaceuticals achieved consolidated revenue of ₹43,590.17 million. The consolidated profit for the year stood at ₹2,563.97 million. On a standalone basis, the company reported annual revenue of ₹13,487.36 million and a net profit of ₹1,116.40 million for the same period.
Dividend and Record Date
The Board has recommended a final dividend of ₹1.00 (50%) and a special dividend of ₹2.00 (100%) per equity share of ₹2 face value. This payout is subject to shareholder approval at the company’s 22nd Annual General Meeting. The company has fixed July 3, 2026, as the Record Date to determine shareholder eligibility for these payments.
Leadership and Administrative Updates
The company announced strategic changes within its senior management effective May 14, 2026. Mr. V Jagannathan has been appointed as President – HR, succeeding Mr. Arvind Srivastava, who is stepping down from the role due to structural changes within the organization.
Strategic Appointments
To further strengthen its audit and compliance framework, the Board has re-appointed M/s. Balwinder & Associates as Cost Auditors for F.Y. 2026-27. Additionally, Mahajan & Aibara LLP has been appointed as the new Internal Auditors for the upcoming fiscal year, reinforcing the company’s commitment to robust financial oversight.
Annual General Meeting
Shareholders are invited to attend the 22nd Annual General Meeting, which is scheduled to take place on Friday, July 10, 2026, at 11:00 AM IST via video conferencing and other audio-visual means. The notice and the Integrated Annual Report for the year ended March 31, 2026, will be disseminated to shareholders in due course.
Source: BSE
